You are in: eMedicine Specialties > Otolaryngology and Facial Plastic Surgery > NASAL AND SINUS DISEASES BarosinusitisArticle Last Updated: May 26, 2006AUTHOR AND EDITOR INFORMATIONAuthor: J Kim Thiringer, DO, Director for Organizational Excellence, Department of Otolaryngology-Head and Neck Surgery, Naval Medical Center, San Diego J Kim Thiringer is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery Editors: Lanny Garth Close, MD, Chair, Professor, Department of Otolaryngology-Head and Neck Surgery, Columbia University College of Physicians and Surgeons; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Stephen G Batuello, MD, Consulting Staff, Colorado ENT Specialists; Christopher L Slack, MD, Otolaryngology-Facial Plastic Surgery, Private Practice, Associated Coastal ENT; Medical Director, Treasure Coast Sleep Disorders; Arlen D Meyers, MD, MBA, Professor, Department of Otolaryngology-Head and Neck Surgery, University of Colorado School of Medicine Author and Editor Disclosure Synonyms and related keywords: barosinusitis, sinus barotrauma, sinus squeeze, sinus inflammation, paranasal sinus barotrauma, barotrauma, sinus INTRODUCTIONBackgroundBarotrauma of the paranasal sinuses is a risk factor for anyone exposed to ambient pressure changes. These pressure changes most often result from travel through mountainous regions, flying, or diving. Barosinusitis is characterized by inflammation of one or more of the paranasal sinuses. Inflammation is caused by a pressure gradient, almost always negative, between the sinus cavity and the surrounding ambient environment. PathophysiologyThe paranasal sinuses have rigid walls with relatively small ostia for gas exchange and mucus transport. Physical gas laws, particularly Boyle's Law, apply to this space. Boyle's Law states that at constant temperature, the volume of a gas is inversely proportional to the pressure placed upon it. To show how Boyle's Law affects the sinuses, consider the case of an individual with normal sinuses exposed to pressure changes while flying in an unpressurized aircraft. As the individual transitions to higher altitude, the ambient pressure surrounding the sinus cavity decreases, and the air in the sinuses expands and equalizes through the natural ostium. Upon descent, ambient air pressure increases, the air in the sinuses contracts, and air moves into the sinus cavity, preventing a pressure gradient from developing. Now consider the same flight in someone who has an upper respiratory tract infection (URTI) with tissue edema and secretions blocking the natural sinus ostia. In this individual, tissue edema and debris will not allow free pressure equalization. Again, as the individual moves up in altitude, the ambient pressure decreases, and volume in the sinus cavity increases. A positive pressure develops in the sinus. With this positive pressure, tissue edema gradually decreases enough to allow debris and air to escape the natural ostium. Air pressure then equalizes. When the individual descends, the ambient pressure increases. Pressure cannot equalize across the nasal cavity to the sinus because of blockage at the ostium. Air volume decreases in the sinus cavity, creating a negative pressure. At this point, a condition exists in which the volume of the sinus must be filled if the pressure gradient is to be eliminated. In mild-to-moderate cases, vascular engorgement and generalized submucosal edema occur. Over time, transudate and mucus fill the volume, reducing negative pressure and decreasing symptoms. In severe cases, especially with rapid onset, the sinus mucosa is stripped from the subjacent bone, resulting in severe pain and hematoma formation. FrequencyUnited StatesPrevalence is approximately 3-4 episodes per 100,000 exposures in a generally healthy population.
RaceRace predilection is not widely reported. SexSex predilection is not widely reported. AgeBarosinusitis is not typically reported in children. Frontal sinuses are most frequently affected, and these do not fully develop until late adolescence. In addition, children do not routinely participate in activities that lend themselves to rapid pressure changes. CLINICALHistoryDifferentiate sinus barotrauma from other causes of facial pain and headache. The history is particularly important in shortening the differential. In sinus barotrauma, a condition of barometric pressure change always exists either during or shortly after onset of symptoms.
PhysicalPhysical findings may be relatively sparse in mild cases of barosinusitis. In severe cases, the patient may have marked pain in the forehead, face, and upper teeth. This pain is typically unilateral. Erythema, edema, congested mucous membranes, epistaxis, and tenderness to palpation of the face may occur. CausesThe following activities and conditions place individuals at particular risk for barosinusitis:
DIFFERENTIALSAllergic Rhinitis Malignant Tumors of the Nasal Cavity Malignant Tumors of the Sinuses Nasal Polyps, Nonsurgical Treatment Nasal Polyps, Surgical Treatment Sinusitis, Acute, Medical Treatment Sinusitis, Chronic, Medical Treatment Sinusitis, Ethmoid, Acute, Surgical Treatment Sinusitis, Frontal, Acute, Surgical Treatment Sinusitis, Fungal Sinusitis, Maxillary, Acute, Surgical Treatment Sinusitis, Maxillary, Chronic, Surgical Treatment Sinusitis, Sphenoid, Acute, Surgical Treatment Turbinate Dysfunction
|
| Drug Name | Oxymetazoline 0.05% (Afrin, Allerest, Chlorphed, Dristan) |
|---|---|
| Description | First-line therapy for topical decongestion. Applied directly to mucous membranes, stimulating alpha-adrenergic receptors and causing vasoconstriction. Decongestion occurs without drastic changes in blood pressure, vascular redistribution, or cardiac stimulation. |
| Adult Dose | 3-4 sprays each nostril q12h; caution with >3-5 d of continual use |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; MAOI therapy |
| Interactions | Hypotensive action of guanethidine may be reversed; concurrent administration with methyldopa may result in an increased vasopressor response; concurrent use of MAOIs and ephedrine may result in hypertensive crisis; pressor sensitivity to mixed-acting agents such as ephedrine may be increased; guanethidine potentiates effects of epinephrine and inhibits effects of ephedrine; phenothiazines may reverse action of nasal decongestants such as oxymetazoline; tricyclic antidepressants potentiate vasopressor response and may result in dysrhythmias |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in hyperthyroidism, coronary artery and ischemic heart disease, diabetes mellitus, increased intraocular pressure, or prostatic hypertrophy; because of increase in vasoconstriction, patients with hypertension may experience change in blood pressure; do not use topical decongestants for >3-5 d |
| Drug Name | Phenylephrine 0.5-1% (Neo-Synephrine) |
|---|---|
| Description | First-line topical decongestant if a shorter-acting agent is preferred. Strong postsynaptic alpha-receptor stimulant with little beta-adrenergic activity that produces vasoconstriction of arterioles in the body. |
| Adult Dose | 3-4 sprays each nostril q3-4h; caution with >3-5 d of continual use |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; severe hypertension or ventricular tachycardia |
| Interactions | Bretylium may potentiate action of vasopressors on adrenergic receptors, possibly resulting in arrhythmias; MAOIs may significantly enhance adrenergic effects of phenylephrine, and pressor response may be increased by a 2- to 3-fold factor; guanethidine may increase pressor response of direct-acting vasopressors, possibly resulting in severe hypertension |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in elderly patients, hyperthyroidism, myocardial disease, bradycardia, partial heart block or severe arteriosclerosis; in hypovolemia, use is not a substitute for replacement of blood, fluids and electrolytes, and plasma (promptly restore these when loss occurs) |
| Drug Name | Phenylpropanolamine (Rhindecon, Unitrol, Phenyldrine) |
|---|---|
| Description | Recalled from US market. First-line oral decongestant. Epinephrine stores are released under phenylpropanolamine stimulation and produce alpha- and beta-adrenergic stimulation. These effects may increase outlet resistance. |
| Adult Dose | 25-50 mg PO q4h 75 mg PO q12h sustained release |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; kidney disease, hyperthyroidism, cardiovascular disease, and diabetes; MAOIs within last 14 d; women who are breastfeeding |
| Interactions | May decrease hypotensive effects of guanethidine; hypertensive episode may occur if taken concurrently with indomethacin; phenylpropanolamine may increase pressor effect of beta-blockers |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Contraindicated in women who are breastfeeding; caution in patients with hypertension; may cause nervousness, dizziness, anxiety, headache, irritability, nausea, vomiting, palpitations, and tachycardia |
| Drug Name | Pseudoephedrine (Actifed, Sudafed, Afrin) |
|---|---|
| Description | First-line oral decongestant. Stimulates vasoconstriction by directly activating alpha-adrenergic receptors of the respiratory mucosa. Induces bronchial relaxation and increases heart rate and contractility by stimulating beta-adrenergic receptors. |
| Adult Dose | 60 mg PO q4-6h 120 mg PO q12h sustained release |
| Pediatric Dose | 2-5 years: 15 mg/dose PO q4-6h; not to exceed 60 mg/d 6-12 years: 30 mg/dose PO q4-6h; not to exceed 120 mg/d >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; severe anemia, postural hypertension or hypotension, closed-angle glaucoma, head trauma, or cerebral hemorrhage |
| Interactions | Propranolol, MAOIs, and sympathomimetic agents may increase toxicity; methyldopa and reserpine may reduce effects |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Not indicated in women who are breastfeeding; caution in patients with hypertension; may cause nervousness, dizziness, anxiety, headache, irritability, nausea, vomiting, palpitations, and tachycardia |
Antibiotics control infection either as an inciting factor in the barosinusitis or as a sequela of the barosinusitis.
| Drug Name | Amoxicillin/clavulanate (Augmentin) |
|---|---|
| Description | Drug combination treats bacteria resistant to beta-lactam antibiotics. First-line therapy for persons not allergic. |
| Adult Dose | 500-875 mg PO bid |
| Pediatric Dose | 45 mg/kg/d PO divided bid |
| Contraindications | Documented hypersensitivity to any penicillins; beware of anaphylactic reaction |
| Interactions | Coadministration with warfarin or heparin increases risk of bleeding |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Common adverse effects include diarrhea, nausea, indigestion, skin rash, pruritus, and urticaria; safety in women who are breastfeeding is unknown |
| Drug Name | Trimethoprim/sulfamethoxazole (Bactrim, Septra) |
|---|---|
| Description | First-line therapy in patients allergic to penicillin, although adverse effect profile may make other agents more desirable. |
| Adult Dose | 1 tab PO bid (double strength) |
| Pediatric Dose | 1 tab PO bid (single strength) |
| Contraindications | Documented hypersensitivity; megaloblastic anemia due to folate deficiency; women who are breastfeeding |
| Interactions | May increase PT when used with warfarin (perform coagulation tests and adjust dose accordingly); coadministration with dapsone may increase blood levels of both drugs; coadministration of diuretics increases frequency of thrombocytopenia purpura in elderly patients; phenytoin levels may increase with coadministration; may potentiate effects of methotrexate in bone marrow depression; hypoglycemic response to sulfonylureas may increase with coadministration; may increase levels of zidovudine |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Do not use if breastfeeding; may prolong bleeding time in those on warfarin; may increase anticonvulsant levels; severe reactions (eg, Stevens-Johnson syndrome, hepatic necrosis, aplastic anemia, epidermolysis) may occur; causes photosensitivity |
| Drug Name | Cefuroxime (Ceftin, Zinacef) |
|---|---|
| Description | Second-line therapy, but may be first-line therapy in patients who are allergic to penicillin. |
| Adult Dose | 250-500 mg PO qd or divided bid |
| Pediatric Dose | 15 mg/kg/dose PO bid |
| Contraindications | Documented hypersensitivity |
| Interactions | Disulfiramlike reactions may occur when alcohol is consumed within 72 h after taking cefuroxime; may increase hypoprothrombinemic effects of anticoagulants; may increase nephrotoxicity in patient receiving potent diuretics such as loop diuretics; coadministration with aminoglycosides increase nephrotoxic potential |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Generally well tolerated; safety during breastfeeding unknown; most common adverse effects include nausea and diarrhea |
| Drug Name | Amoxicillin (Trimox, Amoxil) |
|---|---|
| Description | Interferes with synthesis of cell wall mucopeptides during active multiplication resulting in bactericidal activity against susceptible bacteria. |
| Adult Dose | 500 mg PO q8h; not to exceed 3 g/d |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Reduces efficacy of oral contraceptives |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in renal impairment. |
Acetaminophen, with or without codeine, is useful for pain control.
| Drug Name | Acetaminophen with codeine (Tylenol and codeine) |
|---|---|
| Description | First-line analgesic for severe pain. Fixed combination Tylenol #3 is 300-mg acetaminophen with 30-mg codeine. |
| Adult Dose | 1-2 tab PO q4h |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Toxicity increases with CNS depressants or tricyclic antidepressants |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | May result in acute opiate withdrawal symptoms in patients dependent on opiates; caution in severe renal or hepatic dysfunction. |
| Drug Name | Acetaminophen (Feverall, Tempra, Tylenol) |
|---|---|
| Description | DOC for pain in patients with documented hypersensitivity to aspirin, NSAIDs, upper GI disease, or on oral anticoagulants. |
| Adult Dose | 650-1000 mg PO q4-6h |
| Pediatric Dose | 15 mg/kg/dose PO q4h |
| Contraindications | Documented hypersensitivity |
| Interactions | Rifampin can reduce analgesic effects of acetaminophen; coadministration with barbiturates, carbamazepine, hydantoins, and isoniazid may increase hepatotoxicity. |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Various dose levels of acetaminophen can induce hepatotoxicity in persons with chronic alcoholism |
Article Last Updated: May 26, 2006